Figure 4.

Summary histograms of the effects of intravesical instillation of a CXCR3 receptor antagonist (AMG487; 5 mg/kg) on bladder capacity defined as infused volume (μl) (A) to elicit a micturition reflex and the number (#) of non-voiding contractions (NVCs/micturition cycle) (B) (increases in bladder pressure of ≥5 cm H₂0 during the filling phase without the release of urine) in control and CYP-treated (4 h, 48 h) female mice. Bladder function testing was performed before (pre) and after (post) intravesical administration of a CXCR3 receptor antagonist in the same groups of control, 4 h and 48 h CYP-treated mice. Intravesical instillation of AMG487 (5 mg/kg) significantly (p ≤ 0.01) increased volume infused (μl) (A), and significantly (p ≤ 0.01) decreased the # of NVCs/cycle (B) in 4 h and 48 h CYP-treated female mice. *p ≤ 0.01 compared to pre AMG487 treatment. ^#p ≤ 0.01 compared to control (before or after AMG487 treatment). Sample sizes are n = 8–10 in each group.